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Abstract In this article we review the basis for current
anti-mitotic, anti-cancer, therapy and the potential for
Aurora B kinase inhibitors as a new differentiated class of
agents—“mitotic drivers”. We review the current under-
standing of Aurora B inhibition from basic cell biology to
inhibitors currently undergoing clinical trials.
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1 Introduction
Errors in mitosis can lead to genomic instability and the
development of cancer. In the past decade there has been a
dramatic increase in the understanding of the underlying
biological machinery “that performs this essential cellular
process, and the subtle ways in which it can malfunction in
cancer. As a direct consequence of this increased under-
standing new drug targets have been identified that hold the
promise of enhanced efficacy and reduced toxicity when
compared to other cytotoxic approaches. One prototypical
example is the Aurora B. This kinase was first demonstrat-
ed to be cancer associated (overexpressed in colon tumours
as compared to adjacent normal tissue) in 1998 [1]. In the
intervening period the Aurora kinases have been the
focus of intense academic and industrial effort currently
culminating in multiple clinical trails with a diverse
array of inhibitors. Here we review the background biology,
current status and future directions for these exciting new
anticancer agents.
2 Antimitotics—drugs which block mitosis
2.1 Microtubule toxins and the history of the antimitotic
concept
The medicinal properties of the so called antimitotic agents
has been appreciated for a long time; plant extracts
containing colchicine have been used to treat gout for
centuries [2]. Today, a large array of antimitotics including
the taxanes (e.g. paclitaxel, docetaxel) and the vinca alkaloids
(e.g. vincristine, vinblastine) are used routinely in the clinic,
primarily to treat cancer [3]. In the United Kingdom, about
75% of women with ovarian cancer receive paclitaxel in
combination with a DNA damaging agent as a first-line
therapy [4]. The widespread use of antimitotics is well
founded; two comprehensive reviews of Phase III clinical
trials showed that the inclusion of taxanes in adjuvant
chemotherapy regimens for breast cancer improved disease
free survival and overall survival [5, 6].
The common feature of the antimitotics is that they all
bind tubulin [3]; indeed, tubulin was discovered via its
ability to bind colchicine [7]. By binding tubulin, the
antimitotic compounds suppress microtubule dynamics
which has a profound effect on cells during mitosis.
Dynamic microtubules are required to build the bipolar
spindle which is then used to accurately segregate the
duplicated chromosomes to daughter cells [3]. When
spindle assembly is inhibited, the spindle checkpoint is
activated, thereby inducing mitotic arrest, a phenomenon
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which has been appreciated for over 100 years [8]. Indeed,
its is the prolonged mitotic arrest that gives this class of
compounds its name. Following prolonged mitotic arrest,
tumour cells typically die, either directly in mitosis or
following mitotic exit [9].
The therapeutic strength of the antimitotics is also their
weakness. Dividing tumour cells need dynamic microtubules
to divide, explaining why the antimitotics are effective
against cancer cells. However, because microtubules are
required for a plethora of cellular functions, the anti-tubulin
drugs are toxic to normal cells, both dividing and non-
dividing, i.e. these drugs are cytotoxins. As is typical with
other cytotoxins, toxicity towards normal dividing cells
manifests as myelosuppression. The impact on the immune
system is reversible and therefore clinically manageable.
However, side affects associated with antimitotics that are
not typical of other cytotoxins are peripheral neuropathies,
caused by the inhibition of microtubule-dependent processes
in axons and glial cells [10]. These neuropathies can
manifest as loss of sensation in the extremities and can be
irreversible. In the last 10 years, much efforts has been
spent on trying to bypass this latter problem. If one assumes
that the efficacy of the anti-tubulin drugs is due to their
antimitotic properties, then in principle, compounds that
prevent mitotic spindle assembly without affecting micro-
tubules in non-dividing cells should retain anti-tumour
activity but not the associated neuropathies.
2.2 KSP inhibitors—bringing the antimitotic concept
into the 21st centaury
The first clue that it may be possible to develop drugs
which inhibit mitotic spindle assembly without affecting
microtubule dynamics came from a pioneering high through-
put screen using a cell-based phenotypic assay [11]. The
screen was designed to identify compounds which induced
mitotic arrest, just as the microtubule toxins do. However,
secondary screens were then used to eliminate compounds
which inhibited interphase microtubule dynamics. The
screen yielded a compound which inhibited Eg5, a member
of the kinesin-5 family of motor proteins. Eg5, also known
as kinesin spindle protein (KSP), is a plus-end directed
motor which acts as a homotetramer to cross-link and slide
anti-parallel microtubules at the onset of mitosis, thereby
pushing apart the centrosomes to form the bipolar spindle
[12]. In the absence of Eg5 function, the centrosomes
remain tightly clustered yielding a monopolar spindle;
consequently, the inhibitor was christened Monastrol [11].
Like the tubulin agents, this spindle defect activates the
spindle checkpoint resulting in mitotic arrest.
Monastrol has turned out to be a fantastic research tool,
allowing cell biologists to probe the molecular mechanisms
that regulate spindle assembly and mitotic progression
[see e.g. [13]]. In addition, Monastrol validated KSP as an
attractive anti-cancer drug target. Not only did Monastrol
show that KSP was druggable, but because KSP is only
expressed in proliferating cells and is required only
during mitosis, selective KSP inhibitors should exert anti-
proliferative effects typical of the traditional antimitotics,
but not the associated neuronal toxicity. Indeed, a number
of KSP inhibitors have now been developed as anti-cancer
drugs and clinical trials are underway [14].
One of the forerunners is Ispinesib, also known as SB-
715992 or CK0106023, a quinazolinone derivative which
inhibits the ATPase activity of KSP with a Ki of 12 nM
[15]. Tumour cells treated in culture with submicromolar
doses of Ispinesib arrest in mitosis with monopolar spindles
and then undergo apoptosis. This leads to growth inhibition
in a variety of tumour lines, with a mean GI50 value of
364 nM. Ispinesib appears to be selective for KSP and the
mode of action is due to reduced ADP release. In mouse-
based xenograft models, Ispinesib inhibits tumour growth,
and encouragingly, monopolar spindles were evident in
tumour biopsies, indicating that KSP was targeted in vivo.
Importantly, in Phase I clinical trials with Ispinesib and two
other KSP inhibitors, namely SB-743921 and MK-0731,
neuropathy was not reported as a major side effect; as
expected for a cytotoxin, the dose limiting toxicities were
neutropenia [16–18]. Thus, the KSP inhibitors appear to
have achieved one major goal, namely the elimination of
neurotoxicities. Clearly however, this will count for little if
they do not exert anti-tumour effects comparable with the
existing anti-tubulin agents. Thus far, only a handful of
Phase II trials have reported. Although no objective
responses were observed, it is important to note that these
trials focussed on patients with recurrent or metastatic
diseases including hepatocellular carcinoma, squamous cell
carcinoma and malignant melanoma. A key issue for the
future therefore will be to define which tumour types are
most likely to respond to KSP inhibitors.
2.3 Extending the antimitotic concept—other agents
that inhibit spindle assembly
KSP is only one of many proteins required for spindle
assembly. In the last 10–15 years our understanding of the
molecular mechanisms responsible for spindle assembly,
chromosome alignment, the control of mitotic progression
and cytokinesis has expanded enormously. This basic
knowledge has therefore presented us with a plethora of
novel anti-cancer targets; in principle, inhibition of any
protein required for spindle assembly may yield antimitotic
phenotypes typical of the microtubule toxins and the KSP
inhibitors. The list of potential candidates is now expanding
even faster as genome wide RNAi screens identify yet more
molecules required for spindle assembly [19–21]. However,
186 Cancer Metastasis Rev (2009) 28:185–195
not every protein lends itself to therapeutic intervention;
rather, only a subset of proteins are amenable to drug
discovery, leading to the concept of “the druggable
genome” [22]. One of the largest families in the druggable
genome is the protein kinase family, comprising of both
serine/threonine and tyrosine kinases. Importantly, several
protein kinases are required for spindle assembly, including
the Aurora and Polo-like kinases [23]. Not surprisingly
therefore, based on the antimitotic paradigm, these protein
kinases have received much attention as potential anti-
cancer drug targets [24].
2.4 Aurora A inhibitors—another route to monopolar
spindles
The Aurora family of protein kinases is conserved from
yeast to man [for recent reviews see [25–27]]. While budding
and fission yeast express a single Aurora kinase, Ipl1 and
Ark1 respectively, higher eukaryotes express at least
two Aurora kinases, A and B, with mammals expressing a
third, Aurora C. The founder member of the family,
Drosophila Aurora A, was identified because Aurora
mutations caused abnormal mitoses, largely due to a failure
in centrosome separation yielding monopolar spindles [28].
Based on the antimitotic concept outlined above, this
observation alone suggests that Aurora A might be an
attractive anti-cancer drug target. Indeed, Aurora A has
received an enormous amount of attention from both the
academic and pharmaceutical industry. However, this interest
stems largely from observations that accompanied the
discovery of the human homologue [1]. Firstly, human
Aurora A was discovered in a screen to identify protein
kinases overexpressed in colon cancer. Secondly, Aurora
A localises to 20q13, a region of the genome that is
amplified in some tumours and is associated with poor
prognosis. And finally, overexpression of wild type Aurora
A—but not a catalytically inactive mutant—transformed
rodent cells in vitro. The original rationale behind developing
Aurora A inhibitors therefore was not based on the
antimitotic concept described above, but rather on the
principle that Aurora Awas an oncogene. Thus, the rationale
for targeting Aurora A was that it inhibition might restrain
cellular proliferation in much the same way that Imatinib
inhibits cells expressing BCR-Abl [29].
A plethora of Aurora inhibitors have now been described
[24]. The majority of the early inhibitors yielded pheno-
types consistent with inhibition of Aurora B (see below)
raising the question as to whether it was possible to inhibit
Aurora A in cells with a small molecule. However, in 2006
it was it shown using a dual Aurora A/B inhibitor, ZM3
that it was possible to suppress Aurora A kinase activity in
cells with a small molecule [30]. Encouragingly, this
resulted in a monopolar spindle phenotype, confirming the
observations derived from model organisms [25]. Subse-
quently, a selective Aurora A inhibitor has been described,
namely MLN8054. Developed by Millennium Pharmaceut-
icals, MLN8054 has a benzazepine core scaffold with a
fused aminopyrimidine ring and represents the first Aurora
inhibitor with substantial selectivity for Aurora A over B
having in vitro IC50 values of 4 and 172 nM, respectively
[31]. In cell culture assays MLN8054 also shows selectivity
for Aurora A over B. At 1 μM, MLN8054 blocks Aurora A
T-loop phosphorylation on T288, but little effect on Histone
H3 serine 10 phosphorylation is observed, indicating little
effect on Aurora B activity. Consistent with established
roles for Aurora A, MLN8054 induces abnormal spindles,
often with unseparated centrosomes, and delays progression
through mitosis [31]. This is accompanied by reduced
phosphorylation and localization of the Aurora A substrate
TACC3 [32]. These observations are entirely consistent
with data from model systems, indicating that MLN8054
has potential, not only as a new chemical-biology tool for
probing Aurora A function, but also as a new antimitotic
agent. Surprisingly however, in contrast to the terminal
mitotic arrest induced by anti-microtubule agents and KSP
inhibitors, MLN8054-treated cells ultimately assemble
bipolar spindles, possibly via the formation of ectopic
poles, and then divide, albeit with segregation errors [33].
Whether this is because of incomplete Aurora A inhibition
or the existence of Aurora-A-independent spindle assembly
pathways remains to be seen. Despite the ability of
MLM8054-treated cells to eventually divide, MLN8054
does exert anti-tumour effects in mouse xenograft models.
While the exact mechanism remains to be clarified, the anti-
tumour effects are accompanied by inhibition of Aurora A
activity in vivo as well as spindle defects, consistent with
the notion that the phenomenon is mediated via inhibition
Aurora A.
2.5 Plk1 inhibitors—more monopolar spindles
The founder member of the Polo-like-kinase (Plk) family
was also identified in Drosophila, with polo mutants
displaying a penetrant spindle assembly defect [34, 35].
Mammals express four Plks, with Plk1 being the most
understood. Plk1 localizes to centrosomes, kinetochores,
and then the central spindle in anaphase [Recently reviewed
in [5, 36]]. Plk1’s functions are not simply restricted to
spindle assembly; it has been implicated in the activation of
Cdk1-cyclin B at mitotic entry; centrosome maturation and
spindle assembly; the release of cohesin from chromosome
arms in prophase; and the activation of the APC/C by direct
phosphorylation and inhibition of Emi1. Plk1 also triggers
the initiation of cytokinesis by recruiting Ect2, an exchange
factor for the RhoA GTPase, to the central spindle in
anaphase [Reviewed in [24]]. Despite being involved in a
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several mitotic processes, the predominant phenotype
observed following Plk1 inhibition is a spindle assembly
defect leading to prolonged mitotic arrest. Thus, in contrast
to Aurora A inhibitors, a Plk1 inhibitor may be more
reminiscent of the phenotypes induced by anti-microtubule
agents and KSP inhibitors.
In the last few years a number of Plk1 inhibitors have
been described. Plk1 is inhibited by several generic kinase
inhibitors such as staurosporine and wortmannin [Reviewed
in [24]]. However, the low specificity of these compounds
has limited their use as Plk1 inhibitors. The compound
ON01910 was reported to be a Plk1 inhibitor [37], but in
subsequent studies no inhibition of purified Plk1 was
observed up to 30 μM [38]. Furthermore, the cellular
phenotypes induced by ON01910 were not characteristic
for Plk1 inactivation [39, 40]. More selective Plk1 inhibitors
have recently become available, [Reviewed in [24]]. Of
particular note are BI 2536 and TAL. BI 2536, developed by
Boehringer Ingelheim, is a dihydropteridinone that potently
inhibits Plk1 in vitro with an IC50 of 1 nM. Phenotypes
induced by BI 2536 are consistent with Plk1 inhibition
indicating that it is a good tool for probing Plk1 function [38,
39]. TAL is a thiazolidinone developed by Bayer Schering
Pharma that inhibits Plk1 in vitro with an IC50 of 19 nM.
Again, the phenotypes observed in cell based assays are
entirely consistent with Plk1 inhibition [41]. Importantly,
both BI 2536 and TAL induce a penetrant monopolar spindle
phenotype which in turn activates the spindle checkpoint
resulting in a mitotic arrest phenotype. Thus, in contrast to
Aurora A inhibitors, Plk1 inhibitors do indeed yield pheno-
types more typical of those induced by anti-microtubule
agents and KSP inhibitors. Encouragingly, BI 2536 exerts
anti-tumour effects in xenograft models [38]. When nude
mice harbouring HCT 116 colon cancer derived tumours
were infused i.v. with consecutive cycles of BI 2536 twice
per week, complete tumor suppression was observed.
Importantly, 24 h post-infusion, a massive accumulation of
mitotic cells was observed which was then followed 24 h
later by a wave of apoptosis. These observations indicate that
in vivo, Plk1 inhibition does indeed block mitotic progres-
sion which in turn results in cell death. A number of Plk1
inhibitors are now undergoing clinical evaluation.
3 A new concept—mitotic drivers
3.1 Inhibition of Aurora B overrides the spindle checkpoint
As mentioned above, the initial Aurora inhibitors de-
scribed, such as ZM447439 and Hesperadin, were relative
selective for Aurora B over A [30, 42–44]. Even dual
Aurora inhibitors, such as VX-680, yielded phenotypes
more consistent with Aurora B inhibition [45]. In contrast
to Aurora A, Aurora B is not required for spindle
assembly. Rather, along with survivin, INCENP, and
Borealin, Aurora B is a component of the chromosome
passenger complex (CPC) which localizes to centromeres
in prometaphase [Reviewed in [27]]. It then relocates to
the spindle midzone following anaphase onset. Prior to
anaphase, Aurora B Promotes kinetochore biorientation by
regulating kinetochore–microtubule interactions. Aurora B
is also required for spindle checkpoint activation and
cytokinesis. In prophase, Aurora B phosphorylates histone
H3 on serines 10 and 28. When Aurora B is inhibited,
cells fail to biorient their chromosomes. Normally, this
would be anticipated to activate the spindle checkpoint
leading to a mitotic arrest. However, because Aurora B is
also required for spindle checkpoint function, Aurora-B-
deficient cells enter anaphase and exit mitosis despite the
presence of chromosome malorientations. Cytokinesis
then also fails yielding a cell in G1 but with a 4n DNA
content (see below for more details). This phenotype is
clearly different from that exerted by the so called
antimitotic drugs; where as the microtubule toxins, inhib-
itors of KSP, Aurora A and Plk1 all activate the spindle
checkpoint causing cells to arrest in mitosis, inhibition of
Aurora B overrides the checkpoint and drives cells through
an aberrant mitosis. Therefore, it is not appropriate to
consider Aurora B inhibitors as antimitotic agents; rather,
we suggest that Aurora B inhibitors be termed “mitotic
drivers”.
4 Inhibitors of the Aurora B kinase
4.1 Lessons from cell culture
Since the original association between Aurora A and B
kinase overexpression and cancer was identified, there has
been a huge effort from both academic and industrial
groups to develop small molecule kinase inhibitors to these
targets. The first Aurora inhibitiors to be described were
ZM447439, Hesperadin and VX680[42, 43, 45] and these
remain the best characterised in terms of the publically
available literature [Reviewed in [24]]. ZM447439 shows
20-fold selectivity for Aurora B over A and has proved to
be a useful tool for probing Aurora B function. Similarly,
Hesperadin has been used extensively to probe Aurora B
function; note however that the cytokinesis failure induced
by Hesperadin may be due to an off-target effect in addition
to the inhibition of Aurora B [30]. VX680 is a dual A/B
inhibitor but as with the majority of Aurora inhibitors—the
exception being MLN8054—the predominant phenotypes
in cell based assays arise due to Aurora B inhibition
yielding the mitotic driver phenotype described above.
This, along with the roles of Aurora B in cytokinesis, leads
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to a highly abnormal mitosis with a failure of cytokinesis
but without a cell cycle arrest. These cells maintain an
apparently normal coordinated expression of key cell cycle
regulators such as the cyclins, and will undergo additional
rounds of S-phase and failed mitosis in the presence of an
inhibitor (endeoreduplication) producing enlarged, poly-
ploid cells with multiple centrosomes. When the drug is
removed, it is likely that these cells attempt mitosis but
without a bipolar spindle and in a highly uncoordinated
manner, literally “tearing” the genome apart and leading to
cell death. When tested in vitro, all of the reported Aurora
B inhibitors are highly effective at killing tumour cells
in vitro although the exact mechanism is unclear. Impor-
tantly, since Aurora B is only active in mitosis, inhibitors
should have no effect on cells that do not pass through
mitosis. Indeed, MCF7 cells retained their cloning
potential when exposed to ZM447439 while arrested in
G1 [42].
4.2 Lessons from animal models
Encouragingly, those Aurora kinase inhibitors which are
compatible with in vivo dosing show excellent anti-tumour
activity against human tumour cell lines grown as xeno-
grafts in rodents. VX-680 caused a marked reduction in
tumour size in a human promyelocytic leukemia (HL-60)
xenograft model [45]. In nude mice treated with VX-680 at
75 mg/kg, twice a day intraperitoneally for 13 days, mean
tumour volumes were reduced by 98%. The authors
reported that VX-680 was well tolerated, with a small
decrease in body weight observed only at the highest dose
(5% decrease at 75 mg/kg b.i.d). VX-680 also induced
tumour regression in pancreatic and colon xenograft
models. Encouragingly, inhibition of phosphorylation of
histone H3 and an increase in apoptosis were observed in
histological sections of tumours from treated animals
indicating that Aurora B was effectively inhibited at the
doses used, and that this killed tumour cells in vivo.
Another Aurora kinase inhibitor, PHA-739358 [46], was
also very active in vivo—in this case the authors extended
the work beyond classic tumour xenografts to perhaps more
relevant spontaneous tumour models and transgenic tumour
models. When PHA-739358 was evaluated classic nude
mouse xenograft models, significant growth inhibition was
reported (up to 98% in HL60 xenografts dosed with 60 mg/
kg/day PHA-739358 i.v. for 5 days). Toxicity was reported
to be limited with minimal body weight loss and mild
myelosuppression, both of which were transient with
recovery after treatment. The authors also utilised a rat
DMBA-induced primary mammary carcinoma model that
displays many similarities with human breast cancer.
Administration of 25 mg/kg PHA-739358 to these rats
(twice a day, i.v.) resulted in 75% inhibition of tumour
growth with complete regression in one animal. The
efficacy was similar to that achieved in the xenograft
mouse models. Finally, the authors evaluated the efficacy of
PHA-739358 in the TRAMP transgenic mouse prostate
cancer model. When TRAMP mice were treated for 5 days
bd i.v. with 30 mg/kg of PHA-739358, 3 out of 16 mice
showed tumor regression up to 80%. Again the authors
reported suppression of phospho histone H3 and elevation
of apoptotic markers in treated tumours.
More recent work [47] examined the sequence of events
in tumours treated with AZD1152 (a selective Aurora B
inhibitor—see Table 1) and provides a clear insight into the
fate in vivo of tumour cells exposed to Aurora B inhibitors.
Infusion of AZD1152 to a human tumour xenograft bearing
animal induces a cascade of events—suppression of histone
H3 phosphorylation, progression of mitosis without bio-
rentied chromosomes, failure of cytokinesis leading to
enlarged polypolid cells and elevated levels of apopotosis
and necrosis in the tumour. The authors also evaluated the
effect of this Aurora kinase inhibitor on normal bone
marrow in the treated animals. As would be expected,
inhibition of Aurora B led to loss of bone marrow and
concomitant neutrapaenia. Perhaps surprisingly, there was
little evidence for enlarged or multinucleated cells in treated
bone marrow suggesting that the fate of “normal” bone
marrow cells exposed to an Aurora B inhibitor may be
different than tumour cells (immediate apoptosis in
response to accelerated mitotic slippage?). Encouragingly,
the bone marrow in treated animals recovered to apparently
normal levels 4 days post treatment whilst the effects on the
tumour were prolonged—suggesting that a therapeutic
index may be obtainable for these agents.
4.3 Clinical development
There are currently more multiple Aurora kinase inhibitiors
in clinical trials. With the exception of MLN8054 the
majority are Aurora B selective or dual A/B inhibitors
(Table 1). At present there is little publicly available
information and therefore we will summarize what is know
about the most advanced compounds. In a phase II trial,
PH739358 from Nerviano Life Sciences has resulted in
seven reported cases of stable disease in the solid tumour
setting (out of 36 patients dosed; 4 for >7 months) and
partial/complete responses in the haematological area
(CML). PH739358 is administered as a 6-hour infusion
weekly (×3 q28d). Disappointingly, MK0457/ VX680
(Merck/Vertex) has been discontinued in phase II despite
responses again in CML. This agent was halted due to
reported issues with QTc prolongation. AZD1152, which is
selective for Aurora B is in Phase I in both solid and
haematological (AML) tumours, although there has been no
publication of activity to date. Dose limiting toxicology
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reported for the majority of these agents seems fairly similar
to the “classic” anti-mitotic cytotoxics—bone marrow
suppression (neutropenia), alopecia, nausea and vomiting
and diarrhoea being typical. At this stage we cannot
determine if the therapeutic index for Aurora kinase
inhibitors is greater, less than or equal to classic anti-mitotic
cytotoxics. Nevertheless, it is very encouraging that
responses are being observed (principally in the haemato-
logical area) so early in the development of this class of new
drugs.
5 Clinical challenges—how can we increase the chance
of beneficial outcomes?
We perceive that there are three critical biological questions
that will need to be addressed in order to most effectively
develop these agents in the clinic.
5.1 How does one know that a biologically effective dose
has been achieved in the tumour?
This should be easy to answer in theory—suppression (or
elevation in the case of an Aurora A inhibitor) of
phosphorylation of histone H3 can be readily measured,
for example by using immunohistochemical techniques. For
Aurora B inhibitors this provides a direct measure of target
inhibition at the site, an ideal “biomarker”. Alternatively,
more common markers of proliferation and apoptosis (e.g.
Ki67, cleaved caspases etc) could be employed. Another,
although perhaps less desirable, alternative is to rely on
measuring suppression of bone marrow as a clinical
surrogate for biological activity of these agents.
5.2 Which tumour type(s) either from tissue of origin or based
on genetic defects will be most likely to respond?
This is a much more complex issue. It is clear that response
does not relate simply to expression levels of these kinases,
apart from at the crudest level—cells must be passing
through mitosis where the kinases are expressed and active
in order for the drugs to work, and tissues with a high
mitotic index by definition will express high levels of
Aurora kinases and perhaps be more likely to respond to
treatment. Perhaps unsurprisingly, it is clear that many of
the current clinical agents are being tested in haematolog-
ical cancers that have a combination of a high mitotic index
and ease of accessibility to tumour tissue for biomarker
measurement (indeed these agents seem very active in
in vitro and in vivo models for haematological disease as
outlined above for VX-680 and PHA-739358). However,
we do not currently understand what other factors, genetic
or environmental, contribute to the response (G1 arrest,
apoptosis, continued cycling, senescence etc) of tumour
cells to Aurora B inhibition. Indeed, the response of even
apparently clonogenic cell lines to “simple” antimitotics
can be heterogenous and extremely complex [9]. This is
an area that deserves significant research, since if defined
genetic lesions do confer sensitivity to Aurora kinase
inhibition this would have direct medical benefit—clinical
trials could be greatly reduced in size, increased in speed
and become genuinely hypothesis driven.
5.3 What duration of inhibition is necessary for obtaining
an optimal therapeutic index?
This is a seemingly trivial question, but in real life very
complex to address. The critical issue here is to reduce
effects on normal tissue but optimise effects on tumour. As
we outlined above, the tumour cells will need to pass through
mitosis in the presence of the drug in order to be affected.
This typically sets a minimum exposure time based on the
proliferative index of the tumour. The maximum is a function
of how much ablation of normal proliferating cells can be
tolerated. For most of the current agents in the clinic the
minimum appears to be of the order of a few hours out to a
maximum of 7 days continual infusion, with a wide variety
of cycles and schedules being evaluated. Again, it cannot be
emphasised strongly enough how useful it would be to be
able to pre-select responsive tumours based on their
genotype or other characteristics in order to rapidly narrow
down these dosing regimens.
6 The future
Within a short space of time the initial observations that the
Aurora kinases are overexpressed in cancer have been
translated into the development of drugs that have suitable
properties to investigate their role as a potential new class
of anti-cancer agents, the “mitotic drivers”. Many clinical
trials are now underway with a spectrum of agents that
cover the full range of kinase selectivity from broadly
targeting to exquisite selectivity for a given Aurora kinase.
So far, the data emerging from the clinic are both
encouraging (responses) and disappointing (toxicology).
What directions could future research take in order to
enable us to better use the current generation of Aurora
inhibitors—and are there additional opportunities to target
the machinery of mitosis that may yield genuinely tumour
cell selective killing?
6.1 How can we predict responsive tumour populations?
As we outlined above we believe that it would provide a
major benefit to patients if the genetic basis of the outcome
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of exposure to Aurora kinase inhibitors could be under-
stood. This is a very significant problem in oncology drug
discovery in general, and even in the case of apparently
“simple” agents such as the tubulin binding anti-mitotics
can induce different fates in different cells within an
apparently clonal population. Adding in the complexity of
tumour cell heterogeneity and response to microenviron-
ment and this becomes a very challenging task.
There are however ways that this could be approached—
for example genome scale siRNA “synthetic lethal screen”
in the presence of an Aurora kinase inhibitor (analogous
those performed for PARP inhibitors [48]) that may reveal
genes that interact with Aurora B in a lethal manner. If loss
of any of these genes (or pathways in which these genes
operate) occurs in specific tumour populations then this
could potentially identify tumours that are more sensitive to
inhibition than normal tissue. There are of course many
other approaches that could be taken. Another area that is
currently not well understood is the behaviour of Aurora
kinase inhibition in combination with other anti-cancer
therapeutics from classic cytotoxics through to more recent
specific inhibitors of signal transduction. Identifying com-
binations that have synergistic effects in tumours is clearly
a priority.
6.2 Drug-resistance?
In common with the emergence of resistance seen with
other kinase inhibitors in the oncology setting, it is likely
that the selective pressure placed upon the tumour, coupled
with the inherent genomic instability of tumour cells will
select for evolution of inhibitor resistant kinase mutants.
Indeed, this has already been demonstrated in the in vitro
setting. A recent screen showed that HCT116 cells can
become resistant to ZM447439 by acquiring mutations in
Aurora B [30]. Two mutations mapped to the active site and
probably occlude inhibitor binding while a third mutation,
near the activation loop, appears to hyperactivate the
kinase. These mutations also rendered Aurora B resistant
to other inhibitors namely VX-680, Hesperadin and
MLN8054. It would therefore be valuable to generate and
characterise the behaviour of resistant mutants to the current
agents in the clinic. This could lead to the development of
new compounds that will either overcome resistance
mechanisms or be intrinsically more difficult to evolve
resistance to (for example by allosteric rather than ATP
competitive inhibition).
6.3 Can the mitotic driver concept identify other targets?
Distinguishing antimitotics from mitotic drivers is not a
question of semantics. At present, it is not clear how
antimitotic agents actually exert their anti-tumour effects. It
is well established that antimitotic compounds activate the
spindle assembly checkpoint (SAC) leading to mitotic
arrest. Following prolonged arrest, a number of outcomes
are possible (Fig. 1). While some cells die in mitosis, others
exit mitosis without dividing and return to interphase. Once
back in interphase, some lines undergo cell-cycle arrest,
others die, and others rereplicate their genomes, i.e.,
endocycle [9]. What is not clear however is which of these




























Fig. 1 The mitotic driver
concept. Traditional antimitotic
agents such as the microtubule
toxins disrupt spindle assembly
which leads to a mitotic arrest
phenotype. By contrast, mitotic
drivers—the prototypes being
inhibitors of the Aurora B
kinase—drive cells out of an
aberrant mitosis
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few cell lines is the death in mitosis the dominant behavior.
Most cells eventually return to interphase, a process known
as slippage, before eventually undergoing apoptosis. Per-
haps slippage and death in interphase, as opposed to death
in mitosis, is the more clinically desirable outcome. If this
is the case, then other mitotic drivers, which in effect
accelerate slippage causing exit from an aberrant mitosis,
may also have merit as an anti-cancer agent. In turn, if this
is the case, it opens up the possibility of exploring a number
of other targets, in particular other kinases which are
required for spindle checkpoint function. A number of kinases
are required for checkpoint function in humans including
Bub1, BubR1, Mps1, Tao1 and Prp4 [49]. Inhibitors of these
kinases, either alone or in combination with antimitotic
agent would be expected to drive cells out of an aberrant
mitosis, in other words to act as mitotic drivers.
6.4 Can we inhibit mitosis selectively in tumour cells?
Like the antimitotics and Aurora B inhibitors, SAC
inhibitors would affect all dividing cells and would therefore
be expected to be cytotoxins. The preference would be to
identify targets that preferentially affect tumour cells over
normal cells. One way to do this was reported very recently
in an elegant paper by Kwon and colleagues [20]. They
utilised the observation that tumour cells frequently carry
multiple centrosomes but still form bipolar spindles. They
performed a genetic screen to identify genes that were
responsible for centrosome clustering in Drosophila cells
carrying >2 centrosomes and then characterised human
homologues of these genes in tumour and normal cells.
siRNA inhibition of one of these genes, HSET, led to
unclustering of centrosomes, multipolar mitosis and cell
death specifically in tumour cells with >2 centrosomes,
whilst no effect was observed in normal cells or tumour
cells with a normal centrosome complement. This suggests
that inhibition of HSET, which is an (−) end directed kinesin
motor protein (and therefore likely to be amenable to small
molecule inhibition) could lead to tumour cell specific
killing. Furthermore, it should be relatively straightforward
to identify tumour populations with >2 centrosomes, greatly
focussing clinical trials, should inhibitors be developed.
There are clearly other opportunities to identify and prey
upon tumour cell specific abnormalities in mitosis that
could lead to tumour specific killing. This will be an
exciting area for future research.
7 Summary
In the 10 years since the initial association between Aurora
kinase overexpression and cancer was identified huge
progress has been made in both understanding the basic
biological role of these kinases and in developing small
molecule inhibitors with the rare combination of properties
that enables them to be dosed to man. Elegant work using
these agents and genetic tools has revealed a unique
mechanism of action—forced mitotic drive rather than a
mitotic arrest. This seems very effective in killing tumour
cells in model systems. Encouragingly there are also
indications of activity against real human tumours emerg-
ing. This is impressive given that the majority of patients in
these trials will have failed pre-existing therapies, including
anti-mitotics and indicates that Aurora kinase inhibitors
may have clinical utility.
However there still remains much work to be done to
understand how these agents can be most effectively used
to benefit patients with cancer, and to better understand the
mechanisms by which interference with basic mitotic
mechanisms can kill tumour cells.
Improved understanding here will yield direct benefit to
patients, and may yield the “holy grail”—drugs which
combine the lethality of cytotoxic agents with specificity
for tumour cells.
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